KRW43,000.00
5.78% today
Korea, May 21, 08:10 am CET
ISIN
KR7302440003
Symbol
302440
Index
Sector
Industry

SK Bioscience Target price 2025 - Analyst rating & recommendation

SK Bioscience Classifications & Recommendation:

Hold
33%
Sell
67%

SK Bioscience Price Target

Target Price KRW33,000.00
Price KRW43,000.00
Deviation
Number of Estimates 2
2 Analysts have issued a price target SK Bioscience 2026 . The average SK Bioscience target price is KRW33,000.00. This is lower than the current stock price. The highest price target is
KRW41,000.00 4.65%
register free of charge
, the lowest is
KRW25,000.00 41.86%
register free of charge
.
A rating was issued by 3 analysts: 0 Analysts recommend SK Bioscience to buy, 1 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the SK Bioscience stock has an average upside potential 2026 of . Most analysts recommend the SK Bioscience stock at Sale.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion KRW 267.55 672.47
27.59% 151.35%
EBITDA Margin -48.41% 0.96%
2,809.38% 102.16%

3 Analysts have issued a sales forecast SK Bioscience 2025 . The average SK Bioscience sales estimate is

KRW672b
Unlock
. This is
68.19% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
KRW783b 95.78%
Unlock
, the lowest is
KRW601b 50.22%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 KRW268b 27.59%
2025
KRW672b 151.35%
Unlock
2026
KRW734b 9.09%
Unlock
2027
KRW710b 3.25%
Unlock

3 Analysts have issued an SK Bioscience EBITDA forecast 2025. The average SK Bioscience EBITDA estimate is

KRW6.5b
Unlock
. This is
106.76% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
KRW132b 238.05%
Unlock
, the lowest is
KRW-112b 16.72%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 KRW-130b 2,006.57%
2025
KRW6.5b 105.43%
Unlock
2026
KRW39.9b 516.66%
Unlock
2027
KRW-21.6b 154.23%
Unlock

EBITDA Margin

2024 -48.41% 2,809.38%
2025
0.96% 102.16%
Unlock
2026
5.43% 465.63%
Unlock
2027
-3.04% 155.99%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
EV/Sales 3.92

Based on analysts' sales estimates for 2025, the SK Bioscience stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.60 28.34%
2025
3.92 40.58%
Unlock
2026
3.60 8.33%
Unlock
2027
3.72 3.36%
Unlock

P/S ratio

Current 7.97 35.30%
2025
4.74 40.54%
Unlock
2026
4.34 8.33%
Unlock
2027
4.49 3.36%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today